1.Dermatofibrosarcoma Protuberans on the Chest with a Variety of Clinical Features Masquerading as a Keloid: Is the Disease Really Protuberant?.
Kumiko KIMURA ; Toru INADOMI ; Wataru YAMAUCHI ; Yukihiro YOSHIDA ; Tsutomu KASHIMURA ; Tadashi TERUI
Annals of Dermatology 2014;26(5):643-645
No abstract available.
Dermatofibrosarcoma*
;
Keloid*
;
Thorax*
2.Successful Pre-Operative Local Control of Skin Invasion of Breast Cancer Using a Combination of Systemic Chemotherapy and Mohs Paste
Masahiro TAKEUCHI ; Takefumi KATSUKI ; Kumiko YOSHIDA ; Masahiko ONODA ; Michinori IWAMURA ; Toshihiro INOKUCHI ; Akira FURUTANI ; Tomoe KATOH ; Kazuaki KAWANO ; Keiji HIRATA
Journal of Breast Cancer 2021;24(5):481-490
Locally advanced breast cancer (tumor > 5 cm, widespread infiltration of the skin and muscle, or metastases to lymph nodes) is difficult to resect by surgery, and even when it is resectable, there is a high probability of local recurrence and distant metastasis. Therefore, systemic therapy should be administered first. However, as cutaneous infiltration progresses, the patient's quality of life is impaired by pain, bleeding, presence of exudates, and a foulsmelling odor. Treatment with Mohs paste with systemic therapy can control symptoms associated with skin infiltration and can also be expected to decrease tumor volume.Herein, we report a case in which a tumor was resected following Mohs paste and systemic chemotherapy administration, and the skin defect was reconstructed with a latissimus dorsi myocutaneous flap. We also review the literature for previously reported cases of breast cancer involving Mohs paste.
3.Mode of Imaging Study and Endovascular Therapy for a Large Ischemic Core: Insights From the RESCUE-Japan LIMIT
Fumihiro SAKAKIBARA ; Kazutaka UCHIDA ; Shinichi YOSHIMURA ; Nobuyuki SAKAI ; Hiroshi YAMAGAMI ; Kazunori TOYODA ; Yuji MATSUMARU ; Yasushi MATSUMOTO ; Kazumi KIMURA ; Reiichi ISHIKURA ; Manabu INOUE ; Kumiko ANDO ; Atsushi YOSHIDA ; Kanta TANAKA ; Takeshi YOSHIMOTO ; Junpei KOGE ; Mikiya BEPPU ; Manabu SHIRAKAWA ; Takeshi MORIMOTO ;
Journal of Stroke 2023;25(3):388-398
Background:
and Purpose Differences in measurement of the extent of acute ischemic stroke using the Alberta Stroke Program Early Computed Tomographic Score (ASPECTS) by non-contrast computed tomography (CT-ASPECTS stratum) and diffusion-weighted imaging (DWI-ASPECTS stratum) may impact the efficacy of endovascular therapy (EVT) in patients with a large ischemic core.
Methods:
The RESCUE-Japan LIMIT (Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism Japan–Large IscheMIc core Trial) was a multicenter, open-label, randomized clinical trial that evaluated the efficacy and safety of EVT in patients with ASPECTS of 3–5. CT-ASPECTS was prioritized when both CT-ASPECTS and DWI-ASPECTS were measured. The effects of EVT on the modified Rankin Scale (mRS) score at 90 days were assessed separately for each stratum.
Results:
Among 183 patients, 112 (EVT group, 53; No-EVT group, 59) were in the CT-ASPECTS stratum and 71 (EVT group, 40; No-EVT group, 31) in the DWI-ASPECTS stratum. The common odds ratio (OR) (95% confidence interval) of the EVT group for one scale shift of the mRS score toward 0 was 1.29 (0.65–2.54) compared to the No-EVT group in CT-ASPECTS stratum, and 6.15 (2.46–16.3) in DWI-ASPECTS stratum with significant interaction between treatment assignment and mode of imaging study (P=0.002). There were significant interactions in the improvement of the National Institutes of Health Stroke Scale score at 48 hours (CT-ASPECTS stratum: OR, 1.95; DWIASPECTS stratum: OR, 14.5; interaction P=0.035) and mortality at 90 days (CT-ASPECTS stratum: OR, 2.07; DWI-ASPECTS stratum: OR, 0.23; interaction P=0.008).
Conclusion
Patients with ASPECTS of 3–5 on MRI benefitted more from EVT than those with ASPECTS of 3–5 on CT.
4.QOL Change of Caregivers during First Line Palliative Chemotherapy for Patients with Incurable Cancer
Nobumichi TAKEUCHI ; Saiko KUROSAWA ; Kumiko KOIKE ; Sonomi YOSHIDA
Palliative Care Research 2025;20(1):49-55
Background: Despite the significant physical, emotional, and financial burdens faced by the families of cancer patients, such as caregiving, assisting with hospital visits, and supporting social activities, research on their quality of life (QOL) remains insufficient. Objective: To evaluate the QOL of the families of patients undergoing chemotherapy for cancer and to investigate its relationship with the patients' treatment courses. Methods: A prospective analysis was conducted using EORTC-QLQ-C30 to measure the QOL of patients with unresectable or recurrent solid tumors and their families. Assessments were performed before first-line treatment and before second-line treatment in patients treated at our department between 2016 and 2024. Changes in QOL over the treatment periods and the impact of treatment efficacies were examined. Results: A total of 45 patients were included. Family members frequently reported fatigue, pain, insomnia, and financial difficulties both before and after treatment. Emotional and cognitive functioning declined to the same extent as in patients and did not recover over time. Social functioning notably reduced during the early treatment phase. Treatment efficacy had no impact on the QOL of family members. Discussion: The survey using self-administered questionnaires revealed the consistent need for emotional support for families and highlighted the importance of early social support during the treatment phases.